Status:
COMPLETED
Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome
Lead Sponsor:
AstraZeneca
Conditions:
Zollinger-Ellison Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This research study will determine if esomeprazole, when administered twice daily at 40, 80, or 120 mg doses, can control excessive stomach acid secretion.
Eligibility Criteria
Inclusion
- Males or females at least 18 years of age.
- Diagnosis of Zollinger-Ellison Syndrome or idiopathic hypersecretion
Exclusion
- Pregnant or lactating females
- History of drug addiction or alcohol abuse within 12 months prior to Screening.
- History of intolerance to any proton pump inhibitors or any ingredient in their formulation.
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00079833
Start Date
November 1 2003
End Date
July 1 2005
Last Update
November 19 2010
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Los Angeles, California, United States
2
Research Site
Gainesville, Florida, United States
3
Research Site
Columbus, Ohio, United States
4
Research Site
King of Prussia, Pennsylvania, United States